Photodynamic therapy with verteporfin for retinal angiomatous proliferation

Abstract

Timely PDT with verteporfin in the early stages in eyes with smaller lesions has the potential for a beneficial effect on vision, whereas it might worsen the natural course of larger lesions, with most eyes undergoing enlargement, disciform transformation or RPE tear.

Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration

“…Various treatments for RAP provide poor visual outcomes as shown by conventional laser photocoagulation, 9 transpupillary thermotherapy, 21 surgical ablation, 22,23 or PDT alone. 24,25 Combined therapies may offer better results, especially in case of PDT combined with intravitreal triamcinolone. 26 Finally, the size of our series was limited to 29 eyes of 26 patients.…”

Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP)

“…Various treatment modalities have been used in the treatment of RAP, including direct laser photocoagulation, transpupillary thermotherapy, surgical removal, and photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) with or without concomitant intravitreal triamcinolone [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. However, often their results were disappointing, leading to limited success or to poor functional results, while in some cases concerns were aroused with regard to risks of severe complications [5,16,17].…”

Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation

“…Photodynamic therapy (PDT) has been used as a treatment option in eyes with retinal angiomatous proliferation (RAP) with no favorable results [1,2]. Bevacizumab is a recombinant humanized antibody which binds to all isoforms of VEGF.…”